• Je něco špatně v tomto záznamu ?

Diagnostic and prognostic value of microRNA-21 in colorectal cancer: an original study and individual participant data meta-analysis

H. Zhang, P. Li, H. Ju, M. Pesta, V. Kulda, W. Jin, M. Cai, C. Liu, H. Wu, J. Xu, Y. Ye, G. Zhang, E. Xu, J. Cai, M. Lai, D. Xia, J. Yang, Y. Wu,

. 2014 ; 23 (12) : 2783-92. [pub] 20140901

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, metaanalýza, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15031882

BACKGROUND: We aimed to systematically summarize the diagnostic and prognostic value of circulating/tissue miR21 in patients with colorectal cancer. METHODS: An original study was conducted to explore the potential value of circulating miR21 in colorectal cancer diagnosis and tissue miR21 in colorectal cancer prognosis. PUBMED and EMBASE were searched (to August, 2013) to identify eligible studies. To explore the diagnostic performance of circulating miR21, meta-analysis methods were used to pool sensitivity, specificity, positive and negative likelihood ratio, diagnostic OR and to construct a summary ROC curve. For prognostic meta-analysis, study-specific HRs of tissue miR21 for survival were summarized. Subgroup and sensitivity analyses were applied to explore heterogeneity. RESULTS: Finally, 14 studies (including our study) were included in the meta-analyses. The pooled sensitivity, specificity, and AUC of circulating miR21 were 0.76 [95% confidence interval (CI), 0.59-0.88], 0.81 (95% CI, 0.76-0.85), and 0.81 (95% CI, 0.78-0.85) in diagnosing colorectal cancer. Patients with higher expression of tissue miR21 had significant inferior overall survival (OS; pooled HR, 1.56; 95% CI, 1.16-2.11) and disease-free survival (DFS; pooled HR, 1.35; 95% CI, 1.08-1.69). The individual participant data (IPD) meta-analysis demonstrated that tissue miR21 level was independently associated with worse colorectal cancer OS (HR, 1.69; 95% CI, 1.07-2.67; P = 0.023), whereas this association seems to be confined to males (P = 0.007) but not for females (P = 0.845). CONCLUSIONS: Circulating miR21 level has potential value for colorectal cancer early detection, whereas high tissue miR21 level is associated with adverse colorectal cancer prognosis. IMPACT: miR21 is a promising biomarker for early detection and prognosis of colorectal cancer. Cancer Epidemiol Biomarkers Prev; 23(12); 2783-92. ©2014 AACR.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031882
003      
CZ-PrNML
005      
20151008121504.0
007      
ta
008      
151005s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1055-9965.EPI-14-0598 $2 doi
035    __
$a (PubMed)25178983
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zhang, Honghe $u Zhejiang University School of Medicine, Hangzhou, China. Department of Pathology, Zhejiang University School of Medicine, Hangzhou, China.
245    10
$a Diagnostic and prognostic value of microRNA-21 in colorectal cancer: an original study and individual participant data meta-analysis / $c H. Zhang, P. Li, H. Ju, M. Pesta, V. Kulda, W. Jin, M. Cai, C. Liu, H. Wu, J. Xu, Y. Ye, G. Zhang, E. Xu, J. Cai, M. Lai, D. Xia, J. Yang, Y. Wu,
520    9_
$a BACKGROUND: We aimed to systematically summarize the diagnostic and prognostic value of circulating/tissue miR21 in patients with colorectal cancer. METHODS: An original study was conducted to explore the potential value of circulating miR21 in colorectal cancer diagnosis and tissue miR21 in colorectal cancer prognosis. PUBMED and EMBASE were searched (to August, 2013) to identify eligible studies. To explore the diagnostic performance of circulating miR21, meta-analysis methods were used to pool sensitivity, specificity, positive and negative likelihood ratio, diagnostic OR and to construct a summary ROC curve. For prognostic meta-analysis, study-specific HRs of tissue miR21 for survival were summarized. Subgroup and sensitivity analyses were applied to explore heterogeneity. RESULTS: Finally, 14 studies (including our study) were included in the meta-analyses. The pooled sensitivity, specificity, and AUC of circulating miR21 were 0.76 [95% confidence interval (CI), 0.59-0.88], 0.81 (95% CI, 0.76-0.85), and 0.81 (95% CI, 0.78-0.85) in diagnosing colorectal cancer. Patients with higher expression of tissue miR21 had significant inferior overall survival (OS; pooled HR, 1.56; 95% CI, 1.16-2.11) and disease-free survival (DFS; pooled HR, 1.35; 95% CI, 1.08-1.69). The individual participant data (IPD) meta-analysis demonstrated that tissue miR21 level was independently associated with worse colorectal cancer OS (HR, 1.69; 95% CI, 1.07-2.67; P = 0.023), whereas this association seems to be confined to males (P = 0.007) but not for females (P = 0.845). CONCLUSIONS: Circulating miR21 level has potential value for colorectal cancer early detection, whereas high tissue miR21 level is associated with adverse colorectal cancer prognosis. IMPACT: miR21 is a promising biomarker for early detection and prognosis of colorectal cancer. Cancer Epidemiol Biomarkers Prev; 23(12); 2783-92. ©2014 AACR.
650    _2
$a kolorektální nádory $x diagnóza $7 D015179
650    _2
$a časná detekce nádoru $7 D055088
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a prognóza $7 D011379
650    _2
$a nádorové biomarkery $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Li, Peiwei $u Zhejiang University School of Medicine, Hangzhou, China. Department of Gastroenterology, Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China.
700    1_
$a Ju, Haixing $u Department of Surgical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
700    1_
$a Pesta, Martin $u Department of Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Czech Republic.
700    1_
$a Kulda, Vlastimil $u Department of Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Czech Republic.
700    1_
$a Jin, Wenjun $u Department of Clinical Laboratory, Huzhou Central Hospital, Huzhou, China.
700    1_
$a Cai, Mao $u Anorectal Department, Second Affiliated Hospital, Wenzhou Medical University, WenZhou, China.
700    1_
$a Liu, Changbao $u Anorectal Department, Second Affiliated Hospital, Wenzhou Medical University, WenZhou, China.
700    1_
$a Wu, Han $u Zhejiang University School of Medicine, Hangzhou, China.
700    1_
$a Xu, Jinming $u Zhejiang University School of Medicine, Hangzhou, China. Department of Epidemiology and Health Statistics, Zhejiang University School of Public Health, Hangzhou, China.
700    1_
$a Ye, Yao $u Zhejiang University School of Medicine, Hangzhou, China. Department of Epidemiology and Health Statistics, Zhejiang University School of Public Health, Hangzhou, China.
700    1_
$a Zhang, Guanglin $u Zhejiang University School of Medicine, Hangzhou, China. Department of Pathology, Zhejiang University School of Medicine, Hangzhou, China.
700    1_
$a Xu, Enping $u Zhejiang University School of Medicine, Hangzhou, China. Department of Pathology, Zhejiang University School of Medicine, Hangzhou, China.
700    1_
$a Cai, Jianting $u Department of Gastroenterology, Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China.
700    1_
$a Lai, Maode $u Zhejiang University School of Medicine, Hangzhou, China. Department of Pathology, Zhejiang University School of Medicine, Hangzhou, China.
700    1_
$a Xia, Dajing $u Zhejiang University School of Medicine, Hangzhou, China. Department of Epidemiology and Health Statistics, Zhejiang University School of Public Health, Hangzhou, China.
700    1_
$a Yang, Jun $u State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Department of Biomedicine, College of Biotechnology, Zhejiang Agriculture and Forestry University, Hangzhou, China. georgewuer@126.com gastate@zju.edu.cn.
700    1_
$a Wu, Yihua $u Zhejiang University School of Medicine, Hangzhou, China. Department of Epidemiology and Health Statistics, Zhejiang University School of Public Health, Hangzhou, China. georgewuer@126.com gastate@zju.edu.cn.
773    0_
$w MED00006442 $t Cancer epidemiology, biomarkers & prevention a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology $x 1538-7755 $g Roč. 23, č. 12 (2014), s. 2783-92
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25178983 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20151008121650 $b ABA008
999    __
$a ok $b bmc $g 1092758 $s 915008
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 23 $c 12 $d 2783-92 $e 20140901 $i 1538-7755 $m Cancer epidemiology, biomarkers & prevention $n Cancer Epidemiol Biomarkers Prev $x MED00006442
LZP    __
$a Pubmed-20151005

Najít záznam

Citační ukazatele

Možnosti archivace